Postprandial effects of the phosphodiesterase‐5 inhibitor tadalafil in people with well‐controlled Type 2 diabetes mellitus: a randomized controlled trial

Sjögren, Lena Selin; Olausson, Josefin; Strindberg, Lena; Mobini, Reza; Fogelstrand, Per; Hultén, L; Jansson, Per‐Anders

doi:10.1111/dme.12999

Cited by 9 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies in humans documented as well tadalafil-induced positive metabolic effects in insulin-resistant T2D patients [39][40][41], and in ED men without IR, who showed 30% increase in insulin basal secretion after drug intake [42]. Initially, the principal mechanism describing PDE5i impact Densitometric analysis was calculated as ratio phosphorylated/total proteins and expressed as fold increase vs. c, taken as 1. e Bio-Plex ® suspension array system showed that I (*P < 0.05) but not tadalafil, increased P70/S6K protein phosphorylation vs. control.…”

Section: Discussionmentioning

confidence: 99%

“…RT-qPCRs were performed using 7500 Real Time System (Applied Biosystems ® ) with SYBR-green fluorophore; 40 ng of cDNA were used as template and cycling parameters were 95°C for 10 min, followed by 40 Semiquantitative PCR for PDE5 and PDE11 were performed by using primers and conditions already described by Aversa A. et al [31].…”

Section: Rna Extraction Reverse Transcription Real-time Quantitativementioning

confidence: 99%

See 1 more Smart Citation

The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism

et al. 2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Rna Extraction Reverse Transcription Real-time Quantitativementioning

confidence: 99%

The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, in another randomised, double‐blind, placebo‐controlled study of 42 overweight individuals with prediabetes, 12 weeks treatment with sildenafil significantly increased insulin sensitivity index whilst there was no difference between acute‐ or late‐phase glucose‐stimulated insulin secretion between the sildenafil‐ and placebo‐treated participants 64 . Similarly, acute treatment with tadalafil induced muscle glucose uptake in a fasted and post‐prandial state in a small sample of subjects with T2DM 65,66 . The fasting glucose and insulin levels have, however, remained unchanged.…”

Section: Pde5 Inhibitors and Glucose Metabolism Disordersmentioning

confidence: 97%

“…64 Similarly, acute treatment with tadalafil induced muscle glucose uptake in a fasted and post-prandial state in a small sample of subjects with T2DM. 65,66 The fasting glucose and insulin levels have, however, remained unchanged. Ho et al conducted a randomised, double-blinded, placebo-controlled trial of 53 adults with obesity and elevated fasting insulin levels.…”

Section: It Has Been Established That No Plays An Important Role In M...mentioning

confidence: 99%

The efficacy of PDE5 inhibitors in diabetic patients

Święcicka

2022

Andrology

View full text Add to dashboard Cite

Background: Phosphodiesterase 5 inhibitors (PDE5i), since their introduction in the late 1990s, have proven their efficacy in treating several conditions, predominantly pulmonary hypertension and erectile dysfunction where they remain the first-line therapeutic option. However, in the recent years, growing evidence from both animal and human studies has emerged to suggest the additional benefits of PDE5i in cardiovascular and metabolic disorders. This is of specific interest to the diabetes population where prevalent cardiovascular disease and metabolic dysregulation significantly contribute to the increased morbidity and mortality. Objectives:To examine the available data on the non-standard, pleiotropic effects of PDE5i in patients with diabetes mellitus. Materials and methods:The review of the published background research, preclinical studies and clinical trials. Results:In human studies, PDE5 inhibition appeared to be associated with reduced cardiovascular mortality and overall improved clinical outcomes in those with established cardiovascular disease. PDE5i were also consistently found to reduce albuminuria in subjects with diabetic nephropathy. Furthermore, animal data suggest a plausible effect of this group of medication on sensory function and neuropathic symptoms in diabetic neuropathy as well as improved wound healing. A decrease in insulin resistance and augmentation of beta cell function seen in preclinical studies has not been consistently demonstrated in human trials. Discussion and conclusion:In animal models, PDE5 inhibition appears to decrease oxidative stress and reduce some of the micro-and macrovascular complications associated with diabetes. However, data from human trials are limited and largely inconsistent, highlighting the need for adequately powered, randomised-controlled trials in diabetic cohorts in order to fully assess the benefits of PDE5i in this group of patients.

show abstract

“…In this context, due to their observed antioxidant and anti-inflammatory properties, several studies have highlighted the protective action of PDE5i against endothelial dysfunction and cardiac ischemic/reperfusion [2]. Furthermore, in vivo and in vitro studies have shown how PDE5 inhibition may ameliorate insulin resistance in diabetic mice [20][21][22] and sensitize skeletal muscle cells, adipocytes, and endothelial cells to insulin action, thus improving insulin resistance [13,[23][24][25][26].…”

Section: Introductionmentioning

confidence: 99%

Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue

Antinozzi

Sgrò

Luigi

2020

International Journal of Endocrinology

View full text Add to dashboard Cite

Among metabolic diseases, carbohydrate metabolism disorders are the most widespread. The most common glucose pathological conditions are acquired and may increase the risk of type 2 diabetes, obesity, heart diseases, stroke, and kidney insufficiency. Phosphodiesterase type 5 inhibitors (PDE5i) have long been used as an effective therapeutic option for the treatment of erectile dysfunction (ED). Different studies have demonstrated that PDE5i, by sensitizing insulin target tissues to insulin, play an important role in controlling the action of insulin and glucose metabolism, highlighting the protective action of these drugs against metabolic diseases. In this review, we report the latest knowledge about the role of PDE5i in the metabolic diseases of insulin resistance and type 2 diabetes, highlighting clinical aspects and potential treatment approaches. Although various encouraging data are available, further in vivo and in vitro studies are required to elucidate the mechanism of action and their clinical application in humans.

show abstract

Postprandial effects of the phosphodiesterase‐5 inhibitor tadalafil in people with well‐controlled Type 2 diabetes mellitus: a randomized controlled trial

Cited by 9 publications

References 10 publications

The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism

The phosphodiesterase 5 inhibitor tadalafil regulates lipidic homeostasis in human skeletal muscle cell metabolism

The efficacy of PDE5 inhibitors in diabetic patients

Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue

Contact Info

Product

Resources

About